Meeting
2022 ASCO Annual Meeting
Randomized controlled trial of the efficacy of lymph node dissection on stage IIICr of cervical cancer (CQGOG0103).
Authors
Misi He
Chongqing University Cancer Hospital, Chongqing, China
Misi He , Lin Zhong , Haixia Wang , Ying Tang , Qi Zhou , Dongling Zou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT04555226
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS5604)
DOI
10.1200/JCO.2022.40.16_suppl.TPS5604
Abstract #
TPS5604
Poster Bd #
478b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
First Author: Jihong Liu
Poster
2022 ASCO Annual Meeting
Toripalimab combined with chemoradiotherapy for patients with locally advanced cervical squamous cell carcinoma.
First Author: Dan Ou
Poster
2019 ASCO Annual Meeting
CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer-A phase III, randomized, double-blind, multicenter study.
First Author: Bradley J. Monk
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection.
First Author: Xiuning Le